CEO and Director
Mr. McFadden brings more than 30 years of successful leadership experience spanning pre-IND drug discovery through the commercialization and has launched over a dozen therapies in neurology, psychiatry, endocrinology and urology. He has over 16 years’ experience in Neuroscience. Previous leadership roles have included Chief Commercial Officer at MPower Health, Chief Commercial Officer at UrovantSciences (Nasdaq: UROV), and SVP Sales and Marketing at AvanirPharmaceuticals (Nasdaq: AVNR). Prior to these roles, Mr. McFadden held leadership roles at Amylin Pharmaceuticals (Nasdaq: AMLN) and Pharmacia. He serves on advisory boards at MPower Health and MindLab.
Currently, Dr. Robert Cantu’s professional responsibilities include those of Clinical Professor Department of Neurosurgery and Co-Director Center for the Study of Traumatic Encephalopathy, Boston University School of Medicine, Boston, MA; Senior Advisor to the NFL Head, Neck and Spine Committee; Section Co-Chair Mackey-White National Football League Players Association Traumatic Brain Injury Committee; Co-Founder and Chairman Medical Advisory Board Sports Legacy Institute, Waltham, MA; Adjunct Professor Exercise and Sport Science and Medical Director National Center for Catastrophic Sports Injury Research, University of North Carolina, Chapel Hill, NC; Co-Director, Neurologic Sports Injury Center, Brigham and Women’s Hospital, Boston, Chief of Neurosurgery Service, Chairman Department of Surgery, and Director of Sports Medicine at Emerson Hospital in Concord, Massachusetts, He also serves on the Board of Trustees as Vice President of NOCSAE (National Operating Committee on Standards for Athletic Equipment) as well as Chair of the Scientific Advisory Committee to NOCSAE; Vice President Association Ringside Physician; Neurosurgical Consultant Boston Eagles football team, and Neurosurgical Consultant Boston Cannons professional soccer team. Dr. Cantu also consults with numerous NFL, NHL and NBA teams.
Dr. Elaine Peskind'sresearch over the past 35 years has addressed brain stress hormone systems in aging and Alzheimer’s disease, treatment of cognitive and behavioral problems in Alzheimer's Disease, and cerebrospinal fluid biomarkers in Alzheimer’s disease and related neurodegenerative dementing disorders. Dr. Peskind is Co-PI of a national multi-center study of prazosin for disruptive agitation in Alzheimer’s disease funded by the Alzheimer’s Disease Cooperative Study. More recently, Dr. Peskind’sresearch has focused on combat trauma posttraumatic stress disorder and the clinical phenomenology as well as neuroimaging and cerebrospinal fluid biomarkers of neurodegeneration in combat blast concussion mild traumatic brain injury and in Gulf War Veterans Illness.
Dr. Elaine Peskind continues to conduct single site as well as multi-site large-scale studies of cerebrospinal fluid biomarkers and pharmacological treatment trials for behavioral disorders and traumatic brain injury. Dr. Peskind has over 340 publications and has been continuously funded with Veterans Affairs Merit Review or NIH R01 grants for over 20 years; she is the PI of both the NIA T32 training grant: “Neurobehavior, Neuropathology, and Risk Factors in Alzheimer’s Disease,” and the Mental Illness Research, Education, and Clinical Center Advanced Research Fellowship.
Dr. Elaine Peskind is an elected Fellow of the American College of Neuropsychopharmacology. In 2018, Dr. Peskind was selected as the recipient of the Paul B. Magnuson Award, Veterans Affairs Rehabilitation Research and Development’s highest award for outstanding research in traumatic brain injury, PTSD, and neurodegenerative disorders.
Charles Bernick, MD, MPH, is a staff neurologist with the Cleveland Clinic Lou Ruvo Center for Brain Health. Dr. Bernick has been involved in the field of Alzheimer’s disease research and treatment for over 30 years, beginning as the attending neurologist for the University of California, Davis Alzheimer’s Disease Diagnostic and Treatment Center. Dr. Bernick moved to Las Vegas in 1994 to join the University of Nevada School of Medicine. Since that time, he has directed the development of a statewide network of Alzheimer’s disease care.
In 2009, Dr. Bernick joined the Cleveland Clinic Lou Ruvo Center for Brain Health and has guided the Professional Fighters Brain Health study, a longitudinal cohort study of professional combatants aimed at understanding the effects of cumulative head trauma on brain structure and function.
He graduated summa cum laude from Rice University with a BA degree in history. He received his MD from University of Texas Southwestern, being elected to the medical honor society, alpha omega alpha. Dr. Bernick completed a neurology residency at the University of Miami, followed by a fellowship in neurology at the University of Arizona, and a Masters of Public Health at the University of Nevada, Las Vegas.
Copyright © 2024 A7TBI - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.